CEL-SCI Files Request With The UK's MHRA Regarding Path To Approval For Multikine In The Treatment Of Head & Neck Cancer
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI Corporation (NYSE:CVM) has filed a request with the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for approval of Multikine immunotherapy for the treatment of newly diagnosed head and neck cancer. The company will present new results demonstrating superior pre-surgical response rates and overall survival advantages. CEL-SCI is seeking a pathway towards approval of Multikine throughout the UK and plans to apply for marketing authorization as soon as possible.
October 05, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CEL-SCI's filing with the MHRA for approval of Multikine could potentially open a new market for the company in the UK. The new results demonstrating superior response rates and survival advantages could boost investor confidence.
The news of CEL-SCI filing for approval of Multikine in the UK is directly relevant to the company and its stock. If approved, this could open a new market for the company, potentially increasing its revenues. The new results demonstrating superior response rates and survival advantages could also boost investor confidence in the company and its product, potentially leading to a rise in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100